In connection with the offering to acquire newly issued shares in Isofol and the listing on Nasdaq First North Premier […]
For a complete press release follow the link http://isofol.se/en/ipo/ For additional information, please contact: Anders Rabbe, Managing Director, Isofol Mob: +46 70
Isofol Medical AB announced today that the study ISO-MTX-003 evaluating Modufolin® as rescue therapy (after two cycles of HDMTX treatment)
Isofol Medical AB (publ) announces today that its largest shareholder and co-founder, Bengt Gustavsson, now acquired circa 16 000 shares
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you
In connection with the contemplated IPO of Isofol Medical on Nasdaq First North Premier, we are pleased to invite you
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA,
Isofol Medical AB (publ) today announces that a new patent application was filed, on February 14, 2017, to the US
Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s investigational new drug (IND) application
